Development of prodrug 4-chloro-3-(5-methyl-3-{[4-(2-pyrrolidin-1-ylethoxy)phenyl]amino}-1,2,4-benzotriazin-7-yl)phenyl benzoate (TG100801): a topically administered therapeutic candidate in clinical trials for the treatment of age-related macular degeneration.
J Med Chem
; 51(6): 1546-59, 2008 Mar 27.
Article
in En
| MEDLINE
| ID: mdl-18311895
Full text:
1
Collection:
01-internacional
Database:
MEDLINE
Main subject:
Ophthalmic Solutions
/
Phenols
/
Triazines
/
Prodrugs
/
Macular Degeneration
Type of study:
Prognostic_studies
Limits:
Animals
Language:
En
Journal:
J Med Chem
Journal subject:
QUIMICA
Year:
2008
Document type:
Article
Affiliation country:
Country of publication: